期刊
BREAST CANCER RESEARCH AND TREATMENT
卷 118, 期 3, 页码 523-530出版社
SPRINGER
DOI: 10.1007/s10549-009-0461-7
关键词
Breast cancer; HER2 status; Circulating tumor cells; Predictive markers; Anti-HER2 therapies
类别
资金
- Associazione Italiana Ricerca Cancro (AIRC)-Milan Italy
- Associazione Sandro Pitigliani''-Prato Italy
- Breast Cancer Research Foundation, New York, USA
Biocharacterization of circulating tumor cells (CTCs) in the peripheral blood of advanced breast cancer (ABC) patients may represent a real-time tumor biopsy. We assessed HER2 status on CTCs from blood samples of ABC patients. CTCs were separated and stained using the Cell-Search System (R). HER2 status was assessed by immunofluorescence and, when technically feasible, by fluorescence in situ hybridization. Blood samples were obtained from 66 ABC patients. Forty patients had a positive CTC sample (61%) and of these, 15 (37%) had HER2 ? CTCs. We found non-concordant results in 32% of cases: 29% (8/28) of HER2-negative primary tumors had HER2-positive CTCs and 42% (5/12) of HER2-positive primary tumors had HER2-negative CTCs (k = 0.278). Our study suggests that a subset of patients with HER2-negative primary tumors develops HER2-positive CTCs during disease progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据